Revance raises $45M for a needle-free wrinkle on botox market expansion
This article was originally published in Scrip
Executive Summary
Revance Therapeutics, a private biopharmaceutical company that aims to deliver botulinum toxin and other macromolecules across the skin without needles or other invasive procedures, has raised $45 million in a Series E financing, led by new investor NovaQuest Capital and existing investor Essex Woodlands Health Ventures, joined by several previous investors.